SunTrust Banks, Inc. initiated coverage on shares of AnaptysBio, Inc. (NASDAQ:ANAB) in a research report sent to investors on Wednesday morning. The brokerage issued a buy rating and a $115.00 target price on the biotechnology company’s stock.

A number of other brokerages have also issued reports on ANAB. Royal Bank Of Canada raised their price objective on shares of AnaptysBio from $40.00 to $79.00 and gave the company an outperform rating in a report on Tuesday, October 10th. Credit Suisse Group raised their price objective on shares of AnaptysBio from $38.00 to $85.00 and gave the company an outperform rating in a report on Tuesday, October 10th. Robert W. Baird set a $69.00 price objective on shares of AnaptysBio and gave the company a buy rating in a report on Wednesday, October 11th. Zacks Investment Research lowered shares of AnaptysBio from a buy rating to a hold rating in a report on Wednesday, October 11th. Finally, Stifel Nicolaus reiterated a buy rating and issued a $76.00 price objective (up previously from $35.00) on shares of AnaptysBio in a report on Friday, October 13th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $84.78.

AnaptysBio (ANAB) traded up $2.97 during mid-day trading on Wednesday, hitting $74.86. 507,019 shares of the stock were exchanged, compared to its average volume of 205,320. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.77 and a quick ratio of 10.77. AnaptysBio has a 52-week low of $15.17 and a 52-week high of $78.98.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.02. analysts anticipate that AnaptysBio will post -1.72 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/16/anaptysbio-inc-anab-coverage-initiated-by-analysts-at-suntrust-banks-inc.html.

In other AnaptysBio news, major shareholder Holdings A/S Novo sold 356,300 shares of the stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $21.10, for a total transaction of $7,517,930.00. Following the completion of the sale, the insider now owns 1,936,604 shares of the company’s stock, valued at approximately $40,862,344.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Large investors have recently added to or reduced their stakes in the business. Evercore Wealth Management LLC acquired a new stake in AnaptysBio during the 3rd quarter valued at approximately $100,000. Legal & General Group Plc increased its position in AnaptysBio by 160.8% during the 3rd quarter. Legal & General Group Plc now owns 3,164 shares of the biotechnology company’s stock valued at $110,000 after purchasing an additional 1,951 shares during the period. Bank of America Corp DE acquired a new stake in AnaptysBio during the 1st quarter valued at approximately $123,000. DAFNA Capital Management LLC increased its position in AnaptysBio by 22.2% during the 2nd quarter. DAFNA Capital Management LLC now owns 5,500 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 1,000 shares during the period. Finally, Nationwide Fund Advisors increased its position in AnaptysBio by 89.5% during the 3rd quarter. Nationwide Fund Advisors now owns 5,878 shares of the biotechnology company’s stock valued at $205,000 after purchasing an additional 2,776 shares during the period. 59.04% of the stock is owned by institutional investors and hedge funds.

AnaptysBio Company Profile

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.